Əsas səhifə

Çap

Əks əlaqə

İnfo
Intratympanic gentamicin for Ménière's disease

Mündəricat

Intratympanic gentamicin for Ménière's disease

Sübutlu məlumatların xülasələri
24.10.2017 • Sonuncu dəyişiklik 24.10.2017
Editors

Intratympanic gentamicin may be an effective treatment for vertigo complaints in Ménière's disease, but may carry a risk of hearing loss.

A Cochrane review included 2 RCTs with a total of 50 participants. Both of these trials found a significant reduction in vertigo complaints in the gentamicin group when compared to the placebo group. Due to clinical heterogeneity a meta-analysis could not be performed. One study described an increase in hearing loss in 4 patients (25%) treated with gentamicin while the other described no increase in hearing loss. No other adverse effects were noted by either study.

Comment: The quality of evidence is downgraded by imprecise results (few studies and few patients).

Ədəbiyyat

  1. Pullens B, van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. Cochrane Database Syst Rev 2011;(3):CD008234.